References
- Boucher HW , TalbotGH, BenjaminDKet al. 10 × ‘20 Progress – development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin. Infect. Dis.56, 1685–1694 (2013).
- Butler MS , CooperMA. Antibiotics in the clinical pipeline in 2011. J. Antibiot.64, 413–425 (2011).
- Saleem M , NazirM, AliMSet al. Antimicrobial natural products: an update on future antibiotic drug candidates. Nat. Prod. Rep.27, 238–254 (2010).
- Kinch MS , PatridgeE, PlummerM, HoyerD. An analysis of FDA-approved drugs for infectious disease: antibacterial agents. Drug Discov. Today19 (9), 1283–1287 (2014).
- Kraus CN . Low hanging fruit in infectious disease drug development. Curr. Opin. Microbiol.11, 434–438 (2008).
- Christoffersen RE . Antibiotics – an investment worth making?Nat. Biotech.24, 1512–1514 (2006).
- Fox JL . The business of developing antibacterials. Nat. Biotech.24, 1521–1528 (2006).
- Katz ML , MuellerLV, PolyakovM, WeinstockSF. Where have all the antibiotic patents gone?Nat. Biotech.24, 1529–1531 (2006).
- Anderson AC , PollastriMP, SchifferCA, PeetNP. The challenge of developing robust drugs to overcome resistance. Drug Discov. Today16, 755–761 (2011).
- Hurdle JG , O'NeillAJ, ChopraI, LeeRE. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat. Rev. Microbiol.9, 62–75 (2011).
- Wright GD . Molecular mechanisms of antibiotic resistance. Chem. Commun.47, 4055–4061 (2011).
- UK Five Year Antimicrobial Resistance Strategy 2013–2018. www.gov.uk/government/uploads/system/uploads/attachment_data/file/322358/Outcome_measures.pdf
- Spellberg B , GuidosR, GilbertDet al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis.46, 155–164 (2008).
- O'Neill J . Antimicrobial resistance: tackling a crisis for the health and wealth of nations. http://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
- Brown DG , ListerT, May-DrackaTL. New natural products as new leads for antibacterial drug discovery. Biorg. Med. Chem. Lett.24, 413–418 (2014).
- Walsh CT , WencewiczTA. Prospects for new antibiotics: a molecule-centered perspective. J. Antibiot.67, 7–22 (2014).
- Butera JA . Phenotypic screening as a strategic component of drug discovery programs targeting novel antiparasitic and antimycobacterial agents. J. Med. Chem.56, 7715–7718 (2013).
- Zheng W , ThorneN, McKewJC. Phenotypic screens as a renewed approach for drug discovery. Drug Discov. Today18, 1067–1073 (2013).
- Newman DJ , CraggGM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod.75, 311–335 (2012).
- Hughes J , ReesS, KalindjianS, PhilpottK. Principles of early drug discovery. Br. J. Pharmacol.162, 1239–1249 (2011).
- Swinney DC , AnthonyJ. How were new medicines discovered?Nat. Rev. Drug Discov.10, 507–519 (2011).
- Singh SB . Confronting the challenges of discovery of novel antibacterial agents. Biorg. Med. Chem. Lett.24, 3683–3689 (2014).
- Silver LL . Challenges of antibacterial discovery. Clin. Microbiol. Rev.24, 71–109 (2011).
- Dick T , YoungD. How antibacterials really work: impact on drug discovery. Future Microbiol.6, 603–604 (2011).
- Gwynn MN , PortnoyA, RittenhouseSF, PayneDJ. Challenges of antibacterial discovery revisited. Ann. NY Acad. Sci.1213, 5–19 (2010).
- Williams KJ , BaxRP. Challenges in developing new antibacterial drugs. Curr. Opin. Invest. Drugs10, 157–163 (2009).
- Payne DJ , GwynnMN, HolmesDJ, PomplianoDL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov.6, 29–40 (2007).
- Bumann D . Has nature already identified all useful antibacterial targets?Curr. Opin. Microbiol.11 (5), 387–392 (2008).
- Silver LL . Are natural products still the best source for antibacterial discovery? The bacterial entry factor. Expert Opin. Drug Discov.3 (5), 487–500 (2008).
- Von Nussbaum F , BrandsM, HinzenB, WeigandS, HabichD. Antibacterial natural products in medicinal chemistry – exodus or revival?Angew. Chem. Int. Ed. Engl.45, 5072–5129 (2006).
- Clardy J , FischbachMA, WalshCT. New antibiotics from bacterial natural products. Nat. Biotech.24, 1541–1550 (2006).
- Butler MS , BussAD. Natural products – the future scaffolds for novel antibiotics?Biochem. Pharmacol.71 (7), 919–929 (2006).
- Gullo VP , McAlpineJ, LamKS, BakerD, PetersenF. Drug discovery from natural productsJ. Ind. Microbiol. Biotechnol.33, 523–531 (2006).
- Butler MS . The role of natural product chemistry in drug discovery. J. Nat. Prod.67, 2141–2153 (2004).
- O'Shea R , MoserHE. Physicochemical properties of antibacterial compounds: implications for drug discovery. J. Med. Chem.51, 2871–2878 (2008).
- O'Neill AJ , ChopraI. Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. Expert Opin. Drug Discov.13, 1045–1063 (2004).
- Quinn RJ , CarrollAR, PhamNBet al. Developing a drug-like natural product library. J. Nat. Prod.71, 464–446 (2008).
- Royles BJL . Naturally-occurring tetramic acids – structure, isolation, and synthesis. Chem. Rev.95, 1981–2001 (1995).
- Schobert R , SchlenkA. Tetramic and tetronic acids: an update on new derivatives and biological aspects. Bioorg. Med. Chem.16, 4203–4221 (2008).
- Singh SB , ZinkDL, GoetzMA, DombrowskiAW, PolishookJD, HazudaDJ. Equisetin and a novel opposite stereochemical homolog phomasetin, two fungal metabolites as inhibitors of HIV-1 integrase. Tetrahedron Lett.39, 2243–2246 (1998).
- Jung G , HammesW, GanzleM, MarquardtU, HoltzelA. EP-1116715 (2000).
- Tuske S , SarafianosSG, WangXet al. Inhibition of bacterial RNA polymerase by streptolydigin: stabilization of a straight-bridge-helix active-center conformation. Cell122, 541–552 (2005).
- Phillips JW , GoetzMA, SmithSKet al. Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus. Chem. Biol.18, 955–965 (2011).
- Rosen T , FernandesPB, MarovichMA, ShenL, MaoJ, PernetAG. Aromatic dienoyl tetramic acids. Novel antibacterial agents with activity against Anaerobes and Staphylococci. J. Med. Chem.32, 1062–1069 (1989).
- Matsuo K , KimuraM, KinutaT, TakaiN, TanakaK. Synthesis and antimicrobial activities of 3-acyltetramic acid derivatives. Chem. Pharm. Bull.32, 4197–4204 (1984).
- Matsuo K , KitaguchiI, TakataY, TanakaK. Structure activity relationships in tetramic acids and their copper(II) complexes. Chem. Pharm. Bull.28, 2494–2502 (1980).
- Yendapally R , HurdleJG, CarsonEI, LeeRB, LeeRE. N-substituted 3-acetyltetramic acid derivatives as antibacterial agents. J. Med. Chem.51, 1487–1491 (2008).
- Jeong Y-C , MoloneyMG. Antibacterial barbituric acid analogues inspired from natural 3-acyltetramic acids; synthesis, tautomerism and structure and physicochemical property-antibacterial activity relationships. Molecules20, 3582–3627 (2015).
- Jeong Y-C , MoloneyMG. Tetramic acids as bioactive templates: synthesis, tautomeric and antibacterial behaviour. Synlett2487–2491 (2009).
- Jeong Y-C , MoloneyMG. Synthesis of and tautomerism in 3-acyltetramic acids. J. Org. Chem.76, 1342–1354 (2011).
- Schlenk A , DiestelR, SasseF, SchobertR. A selective 3-acylation of tetramic acids and the first synthesis of ravenic acid. Chem. Eur. J.16, 2599–2604 (2010).
- Jeong Y-C , MoloneyMG, BikadiZ, HazaiE. A detailed study of antibacterial 3-acyltetramic acids and 3-acylpiperidine-2,4-diones. ChemMedChem9, 1826–1837 (2014).
- Jeong Y-C , AnwarM, MoloneyMG, BikadiZ, HazaiE. Synthesis, antibiotic activity and structure-activity relationship study of some 3-enaminetetramic acids. Biorg. Med. Chem. Lett.24, 1901–1906 (2014).
- Jeong Y-C , MoloneyMG. Synthesis and antibacterial activity of monocyclic 3-carboxamidotetramic acids. Beilstein J. Org. Chem.9, 1899–1906 (2013).
- Jeong Y-C , AnwarM, MoloneyMG, BikadiZ, HazaiE. Natural product inspired antibacterial tetramic acid libraries with dual enzyme target activity. Chem. Sci.4, 1008–1015 (2013).
- Tan BSW , ChaiCLL, MoloneyMG, ThompsonAL. Synthesis of mimics of pramanicin from pyroglutamic acid and their antibacterial activity. J. Org. Chem.80, 2661–2675 (2015).
- Smith B , WarrenSC, NewtonGGF, AbrahamEP. Biosynthesis of penicillin N and cephalosporin C – antibiotic production and other features of metabolism of a cephalosporium species. Biochem. J.103, 877–890 (1967).